Aqueous extracts from peppermint, sage and lemon balm leaves display potent anti-HIV-1 activity by increasing the virion density
© Geuenich et al; licensee BioMed Central Ltd. 2008
Received: 19 December 2007
Accepted: 20 March 2008
Published: 20 March 2008
Aqueous extracts from leaves of well known species of the Lamiaceae family were examined for their potency to inhibit infection by human immunodeficiency virus type 1 (HIV-1).
Extracts from lemon balm (Melissa officinalis L.), peppermint (Mentha × piperita L.), and sage (Salvia officinalis L.) exhibited a high and concentration-dependent activity against the infection of HIV-1 in T-cell lines, primary macrophages, and in ex vivo tonsil histocultures with 50% inhibitory concentrations as low as 0.004%. The aqueous Lamiaceae extracts did not or only at very high concentrations interfere with cell viability. Mechanistically, extract exposure of free virions potently and rapidly inhibited infection, while exposure of surface-bound virions or target cells alone had virtually no antiviral effect. In line with this observation, a virion-fusion assay demonstrated that HIV-1 entry was drastically impaired following treatment of particles with Lamiaceae extracts, and the magnitude of this effect at the early stage of infection correlated with the inhibitory potency on HIV-1 replication. Extracts were active against virions carrying diverse envelopes (X4 and R5 HIV-1, vesicular stomatitis virus, ecotropic murine leukemia virus), but not against a non-enveloped adenovirus. Following exposure to Lamiaceae extracts, the stability of virions as well as virion-associated levels of envelope glycoprotein and processed Gag protein were unaffected, while, surprisingly, sucrose-density equilibrium gradient analyses disclosed a marked increase of virion density.
Aqueous extracts from Lamiaceae can drastically and rapidly reduce the infectivity of HIV-1 virions at non-cytotoxic concentrations. An extract-induced enhancement of the virion's density prior to its surface engagement appears to be the most likely mode of action. By harbouring also a strong activity against herpes simplex virus type 2, these extracts may provide a basis for the development of novel virucidal topical microbicides.
Advances in HIV pharmacotherapy led to the current highly active antiretroviral therapy (HAART), which has had significant impact on HIV/acquired immunodeficiency syndrome (AIDS) in the developed world, and these drugs have acted to prolong survival and to alleviate suffering. However, the incidence of side effects and HIV drug resistance in patients under HAART is high  and HIV/AIDS persists as a major cause of morbidity in Western societies and continues to surge unabated in the developing word. Consequently, there remains an urgent need for more potent and conceptually novel antiviral therapeutics to add to current treatment regimens. Over the past decade, the concept of topical microbicides to prevent transmission of HIV has emerged as an important strategy to control the HIV pandemic . The increased incidence of HIV infection in women aged 15–49 years in resource-poor countries has emphasized the need to develop female-controlled, efficacious and safe microbicides for vaginal application [3, 4]. Desirable basic characteristics of topical microbicides include a high in vitro activity against a wide range of HIV-1 strains, a broad activity against other sexually-transmitted pathogens, no-to-low cytotoxicity in in vitro assays, stability under likely storage conditions, low cost, and good acceptance in the target population [3, 4].
Plants of the Lamiaceae family are used in traditional and complementary medicine, in particular in phytotherapy. A virucidal activity of extracts from lemon balm has been reported for herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) [5–7], and recently been extended to other species of the Lamiaceae family . HSV-2 is the major cause of genital ulcerative disease. Here, we explored the antiviral potency of aqueous extracts prepared from dried leaves from lemon balm, peppermint and sage against HIV-1.
Potent anti-HIV activity of aqueous extracts from sage, peppermint, and lemon balm
We systematically investigated the potency of aqueous extracts prepared from dried leaves of well known members of the Lamiaceae family, lemon balm, peppermint, and sage to inhibit HIV-1 infection in vitro and ex vivo. We employed an experimental set-up that allowed us to study potential effects that aqueous extracts may have on HIV virions as well as on intracellular steps of the viral replication cycle. To this end, stocks from the prototypic X4 HIV-1NL4-3 strain were first incubated with concentrations of aqueous extracts ranging from 0.006 to 6% for 1 h at 37°C and subsequently, these suspensions were mixed with an equivalent volume of culture medium and added to the human T-lymphoblastoid cell line Sup-T1. Following overnight exposure, cells were washed, and cultivated for four more days (in the absence of extract). Then, productive HIV-1 infection was assessed by the p24 concentration in culture supernatants.
Selectivity indices of aqueous Lamiaceae extracts in different HIV-1 infection models
IC50 (%) a
CC50 (%) b
Selectivity Index c
0.020 ± 0.012
0.38 ± 0.086
103 ± 66 (6)
0.033 ± 0.020
> 63 ± 19 (4)
0.004 ± 0.002
> 1834 ± 930 (4)
0.054 ± 0.016
9.433 ± 0.463
210 ± 42 (3) d
0.190 ± 0.124
1.700 ± 0.497
71 ± 29 (6)
0.026 ± 0.016
> 191 ± 87 (2)
0.005 ± 0.001
> 208 ± 40 (3)
0.666 ± 0.159
> 19 ± 6 (3) d
0.099 ± 0.066
1.742 ± 0.526
73 ± 28 (4)
0.016 ± 0.005
> 82 ± 20 (4)
0.009 ± 0.004
> 198 ± 70 (3)
1.157 ± 0.672
> 22 ± 9 (3) d
We then extended our analyses to the primary human lymphoid aggregate culture (HLAC) model. These dispersed tonsil tissues are permissive for HIV-1 infection independent of exogenous stimulation [10, 11] providing a biologically relevant experimental ex vivo model system of HIV infection with preserved endogenous cytokine milieu and a heterogeneous pool of primary target cells. All three extracts markedly inhibited HIV-1 infection in HLAC (Fig. 2B, Table 1). Interestingly, Lamiaceae extracts displayed no cytotoxicity in HLAC up to concentrations of 10% in the majority of experiments performed (Fig. 2B, Table 1).
Furthermore, a continuous treatment of monocyte-derived macrophages with lemon balm extract for 16 days at concentrations up to 3% was not cytotoxic (Fig. 2E). More importantly, infection of these primary cells by the macrophage-tropic R5 HIV-1 strain YU-2 was drastically inhibited in the presence of the extract with an endpoint IC50 of 0.018% (Fig. 2C, D). Collectively, these experiments identify a potent antiviral activity of aqueous leaf extracts from three well known species of the Lamiaceae family against X4 and R5 HIV-1 strains at non-cytotoxic concentrations in in vitro and ex vivo primary cell models of HIV-1 infection.
Aqueous Lamiaceae extracts target the HIV-1 virion
The HIV-1 life cycle is characterized by an ordered sequence of events that offers multiple theoretical opportunities for antiviral agents to interfere with replication. To gain first insight into the mode of action of the antiviral activity of Lamiaceae extracts, we performed a side-by-side comparison of, on one hand, the effect of extract exposure of both virions and target cells, in principle as described above (Fig. 1), with, on the other hand, a second experimental set-up, in which target cells were first exposed to extracts for 1 h and extracts then washed off prior to HIV-1 challenge.
Virion fusion is inhibited by aqueous Lamiaceae extracts
In a next step, we employed a sensitive HIV virion-fusion assay to assess whether the earliest events in the infection process, i.e. the interaction of virions with the HIV receptor complex and subsequent membrane fusion, are affected by extract exposure. This assay system is based on the incorporation of β-lactamase-Vpr chimeric fusion proteins (BlaM-Vpr) into replication-competent HIV-1 virions during virus production and their subsequent delivery into the cytoplasm of the target cells as a consequence of virion fusion. BlaM-Vpr-mediated cleavage of the fluorescent CCF2 substrate, which is loaded into target cells, allows a sensitive detection of virus entry and can be quantified by flow cytometry .
To address whether the pronounced effect on HIV-1 entry could fully account for the antiviral effect seen on HIV-1 replication, a HIV-1NL4-3 BlaM-Vpr stock was exposed to different concentrations of lemon balm extract and, subsequently, analyzed separately in the virion-fusion assay and in the HIV-1 replication assay on C8166 T-cells. The dose-response curves of both analyses were remarkably similar (Fig. 4B). This suggested that the inhibition of HIV-1 entry is the major mechanism by which antiviral activity is achieved by lemon balm extract.
Lemon balm extract efficiently inhibits enfuvirtide-insensitive HIV-1 strains
Based on the finding that Lamiaceae extracts affect viral infectivity by inhibiting HIV-1 fusion, we tested whether their virucidal activity may be different for HIV-1 strains carrying env mutations which confer partial resistance to the fusion inhibitor enfuvirtide [14, 15]. Both HIV-1NL4-3 env mutant strains (V38A, X23) were as susceptible to the antiviral effect of lemon balm extract as the wildtype strain in a luciferase reporter assay on TZM-bl cells (Fig. 5A), while mutants required higher concentrations of enfuvirtide to inhibit infection compared to the wildtype strain, as reported previously [14, 15].
The anti-HIV-1 activity in lemon balm extract is rapid, but reduced against surface-bound virions
To study the kinetics of the extract-mediated antiviral activity, HIV-1 virions were either pretreated with lemon balm extract for 1 h at 37°C prior to addition to target cells, reflecting the standard experimental set-up described for the above experiments, or added to target cells simultaneously with the extract. Remarkably, both conditions displayed an equivalent antiviral potency (Fig. 5B), suggesting an immediate impact of the activity. In contrast, surface-bound virions, which had been preadsorbed to TZM-bl cells at 4°C, were at least 100-fold less susceptible to the extract-mediated inactivation (Fig. 5C). Collectively, free virus particles are the prime target of a rapidly acting antiviral activity present in Lamiaceae extracts.
Lemon balm extract does not inhibit HIV-1 Env-mediated cell-cell fusion
Aqueous extracts inhibit HIV-1 particles carrying R5 Envs or the glycoprotein from vesicular stomatitis virus, as well as Moloney murine leukemia virus
Since it is not known which component(s) mediate(s) the anti-HIV activity within the three Lamiaceae extracts, we wondered whether they could act synergistically. To this end, HIV-1 GFP reporter viruses were exposed to concentrations of 0.1% or 0.6% of either extracts from sage, lemon balm or peppermint, or a mix of all three extracts at the identical final concentration, and assayed on TZM-bl cells. Within each of these two concentration groups, the degree of inhibition by all four extract conditions was statistically indistinguishable (data not shown), thus providing no evidence for a synergism in the extracts' anti-HIV-1 activity. As an additional characterization, extract dialysis suggested that the active antiviral compounds in lemon balm extract are larger than 12 kDa (Fig. 7E).
Virion stability and virion-associated levels of Env and processed Gag are not affected by lemon balm extract
Virion density is enhanced by aqueous Lamiaceae extracts
This study identifies a potent anti-HIV-1 activity in aqueous extracts from dried leaves of three well known plants. The major antiviral activity of these tea-like extracts from lemon balm, peppermint, and sage targets the HIV-1 virion. The extracts inhibited the capacity of virions to enter into target cells at concentrations typically two orders of magnitude below the cytotoxic concentrations. A strong antiviral activity was observed for different types of virions carrying a broad spectrum of viral envelopes, but not against the non-enveloped adenovirus type 5.
The cardinal antiviral activity of aqueous Lamiaceae extracts appears to be virucidal and through this mechanism affecting the interaction of the virion with the cell. The activity is rapid since even simultaneous addition of virus and extract to cells allowed for full antiviral potency. In contrast, surface-bound virions were largely protected, suggesting that following engagement of the HIV receptor complex, the extract-induced alterations of the virion can either no longer be exerted or loose their functional consequence. At this point, reversible or transient effects of the extracts on the cell surface, that may additionally impede virion fusion, or on intracellular steps of the HIV-1 replication cycle cannot be entirely excluded. Since these extracts inhibited HIV-1 virions carrying different X4 and R5 HIV-1 Envs as well as the heterologous VSV-G, interfered with MoMLV infection, and were previously shown to be highly active against HSV-1 and HSV-2 , a mode of action that does not specifically target the viral envelope seems likely. Of particular note, while the extracts inhibited fusion of HIV-1 particles with cells, we found that lemon balm extract was completely ineffective in blocking HIV-1 Env-mediated cell-cell fusion.
This indicates that the context of the virion membrane may be a prerequisite or even the prime target for the antiviral activity exerted by the Lamiaceae extracts.
Mechanistically, extract exposure induced an accumulation of virions at a higher sucrose density. Physicobiochemically, this cannot be due to an aggregation of particles in a gradient at equilibrium. Instead, this finding suggests an enhancement of the density of HIV-1 particles and this appears to be the most likely correlate of the reduced infectivity, although a causal link cannot be established at this point. Such a density enhancement could, for example, be due to chemical modifications of the proteins, glycans , or lipids of virions by specific extract components, or due to the attachment of extract components to the virus particle. Interesting in this context, Campbell and colleagues showed that the experimental modification of the lipid composition of HIV-1 virions, i.e. by methyl-β-cyclodextrin-induced cholesterol depletion and/or exogenous lipid replenishment, could result in a higher virion density and a reduction in infectivity [22, 23]. Notably, the enhancement in virion density relative to untreated controls appeared to be at least as pronounced following treatment with lemon balm extract (Fig. 9) as the published effects on virions with exogenously modified lipids [22, 23]. Collectively, a plausible mechanistic model is that the extract-induced increase in the density of enveloped virions prevents their attachment to cells.
At antiviral concentrations that were highly effective in in vitro and ex vivo model systems of HIV-1 infection these inexpensive aqueous extracts from leaves of abundant species of the Lamiaceae family are colorless and odorless, fulfilling basic criteria for the development of a topical microbicide. In addition, Lamiaceae extracts as natural products are widely used in food products, including herbal teas and ice creams, as well as in cold medicine and mild sedative agents, indicating a low systemic toxicity and established acceptance in the general population. A number of candidates, including membrane-disrupting detergents and acidifying agents, which are currently under development as topical microbicides, inactivate HIV particles directly . As an interesting comparison, several peptides with anti-HIV activity have been reported that directly interact with the transmembrane subunit of the envelope glycoprotein, preventing virion fusion. Such peptides include SJ-2176 and T20 (enfuvirtide) [24, 25] derived either from the C-terminal heptad repeat of gp41, or, VIRIP, a naturally occurring peptide identified in human hemofiltrate, which also targets gp41 . While both Lamiaceae extracts and these antiviral peptides prevent fusion of HIV particles, their mode of action is quite distinct. The gp41-targeting peptides, on one hand, are highly selective for HIV-1, display virtually no cytotoxicity, and still allow virus binding to the receptor. The complex aqueous extracts, on the other hand, have a broader antiviral activity that is not selective for a specific viral envelope, display moderate cytotoxicity, and appear to modify the particle without affecting its integrity such that already virus attachment may be inhibited.
The SI values of all three Lamiaceae extracts are encouraging for a complex plant extract ranging from >19 to >1834. For comparison, SI values of >40, >50, and >333 have been reported for the topical HIV microbicide candidates cellulose sulphate, polymethylenehydroquinone sulfonate, or the mandelic acid condensation polymer SAMMA for the infection of primary target cells by HIV-1Ba-L . Interestingly, SI values for our aqueous extracts from sage, lemon balm and peppermint ranged from 65 to 2037 for HSV-2 infection . Other investigators have made important contributions to the design and advancement of topical microbicides that can target both HIV and HSV-2 , with the most recent addition of so called molecular umbrellas, including Spm8CHAS .
It will be interesting to explore by which molecular mechanism these extracts enhance the density of HIV-1 particles. Based on the dialysis studies the active components appeared to be >12 kDa and attempts to identify individual compounds with high antiviral activity by bioguided fractionation of aqueous Lamiaceae extracts may enhance their utility as a lead for the development of a topical microbicide for the prevention of transmission of two major sexually-transmitted pathogens, HSV-2 and HIV-1.
The molecular HIV-1 clone of pNL4-3 and its derivative pNL4-3 E- GFP, the latter carrying an egfp gene within the nef locus driven by the 5'-LTR, were obtained from Dr. Malcom Martin (National Institutes of Health (NIH), Bethesda, MD) and Dr. Nathaniel Landau (New York University, New York, NY) respectively, via the NIH AIDS Research and Reference Reagent Program. Pseudotyping with VSV-G, JR-FL Env and YU-2 Env was performed as reported . The molecular clones of HIV-1NL4-3 Env (V38A) and HIV-1NL4-3 Env (X23) were a kind gift from Dr. Matthias Dittmar (University of Heidelberg, Heidelberg, Germany) . The X23 env gene was derived from a T20-naive HIV-positive individual [14, 15]. Infectious stocks from proviral DNA were generated by transfection of proviral HIV plasmids into 293T cells as described . HIV-1NL4-3 virions containing β-lactamase-Vpr chimeric fusion proteins (BlaM-Vpr) were produced by triple-transfection of 293T cells with pNL4-3 proviral DNA (60 μg), pBlaM-Vpr (20 μg), and pAdVantage (8 μg) vectors (Promega, Madison, WI) per 15-cm2 dish by calcium phosphate DNA precipitation as described [17, 29]. Two days after transfection, culture supernatants were harvested and viral stocks were concentrated using Centricon® Plus-70 spin columns (Millipore, Billerica, MA). After concentration, HIV-1 virions were purified through a 20% or 30% sucrose cushion (44.000 g, 4°C, 60 min), and the virion-enriched pellet was resuspended in phosphate-buffered saline (PBS) and stored at -80°C. The p24 concentration of HIV-1 stocks was determined by antigen enzyme-linked immunosorbent assay (ELISA) as reported . The construction of the replication-competent MoMLV-GFP reporter virus has been reported .
Cell lines, monocyte-derived macrophages and primary rat T-cells
All cell lines and primary macrophages were cultivated under standard conditions in Dulbecco's modified Eagle medium (293T, TZM-bl, MDM) or RPMI 1640 (Sup-T1, C8166, CHO Tat) (both media from GIBCO, Karlsruhe, Germany) supplemented with 10% fetal bovine serum (Invitrogen, Karlsruhe, Germany), 1% penicillin-streptomycin, and 1% L-glutamine (both from GIBCO). Cultures of monocyte-derived macrophages were prepared from Ficoll gradient-purified peripheral blood mononuclear cells isolated from individual, healthy HIV-, HCV-, HBV-seronegative blood donors (DRK Blutspendezentrale, Mannheim, Germany) by adherence and were differentiated in the presence of 10% human AB serum (Invitrogen) for 6–8 days as reported [28, 31]. Cultures of primary rat T-cells were generated as reported [28, 31].
Human Lymphoid Aggregate Culture(HLAC) from tonsil
Tonsil tissue was removed during routine tonsillectomy from HIV-, HBV-, HCV-negative patients with informed consent. To prepare HLAC, tonsil tissue was mechanically dispersed by cutting tissue in 2- to 3-mm blocks and passing them through 40-μm cell strainers (BD Falcon, Belgium). Cells were washed in PBS, and 2 × 106 cells were plated in 96-well V-bottom plates (Corning Incorporated, New York, NY) in a final volume of 200 μl. Culture medium (RPMI 1640 containing 15% fetal bovine serum, 1% L-glutamine, 1% fungizone, 1% gentamycin (all from GIBCO), 0.25% ampicillin (Roth, Karlsruhe, Germany), 1% non-essential amino acids, and 1% sodium pyruvat (both from Invitrogen)). Detailed cultivation methods have been reported [10, 11]. One day after tonsil preparation, the HLAC was inoculated with HIV-1 (5 ng p24 per 2 × 106 cells per well). Where indicated, HIV stocks were preincubated with aqueous Lamiaceae extracts or solvent alone for 1 h at 37°C prior to infection. Following overnight infection cells were washed and the culture medium was subsequently changed every two days without dispersing the pellet. At the same time intervals supernatant samples were harvested and stored at -20°C for subsequent analysis by p24 ELISA.
Aqueous extracts from species of Lamiaceae
Dried leaves from lemon balm (Melissa officinalis L.), peppermint (Mentha × piperita L.), and sage (Salvia officinalis L.) were purchased from Caesar & Lorenz (Hilden, Germany). All plants were identified by microscopy and chromatography according to their monographs in the Pharmakopoea Europoea. Aqueous extracts were prepared as described previously . Briefly, boiling water (100 ml) was added to dried leaves (10 g) and incubated for 15 min, subsequently filtered and cooled down. The resulting extracts were sterile filtered, aliquoted, and stored at -20°C.
Enfuvirtide (Fuzeon®, (T20) Roche, Indianapolis, IN) was freshly dissolved in H2O at 9 mg/ml. Efavirenz (Sustiva®, Bristol-Myers Squibb, Jacksonville, FL) was purchased as a drinking solution at 30 mg/ml and diluted in culture medium. AMD3100 was a kind gift from Dr. José Esté (Badalona, Spain).
Treatment of virus particles and cells
First, virus stocks were incubated with the indicated concentrations (v/v) of aqueous Lamiaceae extracts or H20 as solvent control for 1 h at 37°C. Subsequently, this suspension was mixed with an equivalent volume of culture medium (1:1) and added to target cells (5 ng p24 per 4 × 104 cells). Following overnight exposure, cells were washed and cultivated for 4 more days. Productive HIV-1 infection was assessed by the p24 concentration in culture supernatants.
Exclusive treatment of cells
Cells were exposed to the indicated concentrations of aqueous extracts in culture medium for 1 h at 37°C. Subsequently, the supernatant was discarded, cells were washed once with PBS and challenged overnight with HIV-1 (5 ng p24 per 4 × 104 cells).
Cell viability assay
In parallel to all infection assays, uninfected cells were cultivated in the presence of aqueous Lamiaceae extracts at the identical concentrations used in the infection assays, or in the presence of solvent alone (reference control). Following overnight exposure, cells were washed and cultivated for 3 more days, at which time the cytotoxicity was determined by quantifying the amount of a formazan product metabolized by viable cells from the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution (Sigma) as reported .
HIV-1 virion-fusion assay
The flow cytometry-based HIV-1 virion-fusion assay was performed essentially as described [12, 17, 29]. Briefly, C8166 T-cells were pretreated with enfuvirtide (2 μM), AMD3100 (10 μM), or efavirenz (10 μM) for 15 min. Alternatively, HIV-1NL4-3 BlaM-Vpr virions were pretreated for 1 h at 37°C with the indicated concentrations of aqueous lemon balm extract or solvent. Subsequently, C8166 T-cells were exposed to HIV-1NL4-3 BlaM-Vpr virions (40 ng p24 per 2 × 106 cells) for 6 h, washed and then loaded with CCF2/AM dye overnight. Fusion was monitored with a three-laser BD FACSAria Cell Sorting System (Becton Dickinson, San Jose, CA).
Luciferase reporter virus assay
HIV-1NL4-3 wt virions, or T20-insensitive HIV-1NL4-3 Env (V38A) or HIV-1NL4-3 Env (X23) virions were exposed to lemon balm extract at concentrations from 0.00001 to 1% or solvent for 1 h at 37°C and subsequently added to TZM-bl cells, carrying an LTR-driven firefly luciferase gene. In parallel, TZM-bl cells were pretreated with enfuvirtide at concentrations from 0.0032 to 10 μM for 15 min and then challenged with virus. TZM-bl cells were washed the following day. 48 h after infection a luciferase reporter assay system (Promega) was used to monitor the enzymatic activity.
Cell-Cell fusion assay
This assay was performed in principle as described [16, 17]. Briefly, CHO Tat cells were transiently transfected with expression plasmids encoding for HIV-1 JRFL Env or HIV-1 YU-2 Env together with pCMV-Rev. One day later, transfected CHO Tat cells and TZM-bl cells, the latter stably expressing CD4, CCR5, and an LTR-driven β-galactosidase gene, were harvested and cocultured in a 1:1 ratio in 96-well plates (2 × 104 cells per well in 200 μl of a 1:1 mixture of complete RPMI and DMEM culture medium). Where indicated, transfected CHO Tat cells were exposed to aqueous lemon balm extract or solvent for 1 h at 37°C prior to mixing. The following day, cells were washed once with PBS, and the β-galactosidase enzyme activity and protein concentration in cell lysates were determined with the Galacto-Star™ System (Applied Biosystems) and the BCA™ Protein Assay Kit (Pierce), respectively. The luminometric activity was analyzed with a Luminoskan Ascent (Thermo Labsystems) luminometer and Ascent Software 2.0.
HIV-1 single-round infections
TZM-bl cells were seeded at a density of 1 × 105 cells per well and challenged with single-round HIV-1NL4-3 E- GFP reporter viruses (HIV-1 GFP) pseudotyped with JR-FL Env, YU-2 Env, or VSV-G (all 20 ng p24 per well). Prior to infection, virions were exposed to peppermint extract at concentrations ranging from 0.001 to 1% or solvent for 1 h at 37°C. TZM-bl cells were washed the following day. Three days after infection, the percentage of GFP-positive cells was determined on a FACSCalibur using BD CellQuest Pro 4.0.2 Software (BD Pharmingen).
For the dialysis experiment, lemon balm extract was dialyzed for 24 h at room temperature against water at molecular weight cut-offs of 3.5 or 12 kDa (Spectra/Por® Regenerated Cellulose (RC) Dialysis Membranes). Dialysis-induced changes in extract volume were accounted for prior to virus exposure.
Exploring the activity of lemon balm extract on surface-bound viral particles, TZM-bl cells were inoculated with HIV-1 GFP (200 ng p24 per well) and incubated for 2 h at 4°C. Cells were washed and then solvent or lemon balm extract was added at the indicated concentrations and cells were cultivated at 37°C until analysis.
Western blot analysis
Virions were exposed to lemon balm extract (1%), solvent (H2O; 1%), or Triton X-100 (0.5%) for 1 h at 37°C, pelleted through a 20% sucrose cushion by ultracentrifugation (44.000 g, 4°C, 60 min) and resuspended in PBS (4°C, 30 min) for subsequent analysis by Western blotting. Briefly, samples were boiled in sodium dodecyl sulphate (SDS) sample buffer, separated by 10% SDS-polyacrylamide gel electrophoresis, and transferred onto a nitrocellulose membrane. After incubation with primary antisera (rabbit anti-gp120 Env, 1:5000 (kind gift from Dr. Valerie Bosch, DKFZ, Heidelberg); rabbit anti-24 Gag, 1:4000 (kind gift from Dr. Hans-Georg Kräusslich)) and secondary antibodies (goat anti-rabbit-horseradish peroxidase, 1:10.000; Dianova, Hamburg, Germany), viral structural proteins were detected with an ECL staining solution as reported .
Sucrose-density equilibrium gradient analysis
HIV-1NL4-3 virions (~500 ng p24), which had been purified and enriched by ultracentrifugation through a 30% sucrose cushion, were incubated with either aqueous Lemon balm extract (1%), solvent (H2O; 1%), Triton X-100 (0.5%), or left untreated for 1 h at 37°C. Subsequently, the virion suspensions were loaded onto a 20 to 60% linear sucrose gradient (total volume: 3.5 ml). After ultracentrifugation at 44.000 rpm for 16 h at 4°C in a SW60 rotor, 24 fractions of each 150 μl were carefully collected from top to bottom and the p24 concentration was analyzed. The sucrose density of fractions from an additional tube (without virus) run in parallel was determined by refractometry.
We thank Dr. Hans-Georg Kräusslich for support, reagents and discussion. We are grateful to Drs. Valerie Bosch, Robert Doms, José Esté, Beatrice Hahn, Martin Hartmann, Nathaniel Landau, and Malcom Martin for the gift of reagents. We thank Mrs. Julia Lenz and Dr. Blanche Schwappach for TBD FACSAria analyses. This work was supported by the SFB544 (project B17) from the Deutsche Forschungsgemeinschaft.
- Clavel F, Hance AJ: HIV drug resistance. N Engl J Med. 2004, 350 (10): 1023-1035. 10.1056/NEJM2ra025195.View ArticlePubMed
- Lederman MM, Offord RE, Hartley O: Microbicides and other topical strategies to prevent vaginal transmission of HIV. Nat Rev Immunol. 2006, 6 (5): 371-382. 10.1038/nri1848.View ArticlePubMed
- Keller MJ, Klotman ME, Herold BC: Development of topical microbicides for prevention of human immunodeficiency virus and herpes simplex virus. Am J Reprod Immunol. 2003, 49 (5): 279-284. 10.1034/j.1600-0897.2003.00044.x.View ArticlePubMed
- Turpin JA: Considerations and development of topical microbicides to inhibit the sexual transmission of HIV. Expert Opin Investig Drugs. 2002, 11 (8): 1077-1097. 10.1517/135437184.108.40.2067.View ArticlePubMed
- Cohen RA, Kucera LS, Herrmann EC: Antiviral Activity of Melissa Officinalis (Lemon Balm) Extract. Proc Soc Exp Biol Med. 1964, 117: 431-434.View ArticlePubMed
- Dimitrova Z, B D, Manolova N, Pancheva S, Ilieva D, Shishkov S: Antiherpes effect of Melissa officinalis L. extracts. Acta Microbiol Bulg. 1993, 29: 65-72.PubMed
- Mohrig A: Melissenextrakt bei Herpes simplex – die Alternative zu Nukleosid-Analoga. Dt Apoth Zt. 1996, 136: 109-114.
- Nolkemper S, Reichling J, Stintzing FC, Carle R, Schnitzler P: Antiviral effect of aqueous extracts from species of the Lamiaceae family against Herpes simplex virus type 1 and type 2 in vitro. Planta Med. 2006, 72 (15): 1378-1382. 10.1055/s-2006-951719.View ArticlePubMed
- Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983, 65 (1–2): 55-63. 10.1016/0022-1759(83)90303-4.View ArticlePubMed
- Eckstein DA, Penn ML, Korin YD, Scripture-Adams DD, Zack JA, Kreisberg JF, Roederer M, Sherman MP, Chin PS, Goldsmith MA: HIV-1 actively replicates in naive CD4(+) T cells residing within human lymphoid tissues. Immunity. 2001, 15 (4): 671-682. 10.1016/S1074-7613(01)00217-5.View ArticlePubMed
- Jekle A, Keppler OT, De Clercq E, Schols D, Weinstein M, Goldsmith MA: In vivo evolution of human immunodeficiency virus type 1 toward increased pathogenicity through CXCR4-mediated killing of uninfected CD4 T cells. J Virol. 2003, 77 (10): 5846-5854. 10.1128/JVI.77.10.5846-5854.2003.PubMed CentralView ArticlePubMed
- Cavrois M, De Noronha C, Greene WC: A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes. Nat Biotechnol. 2002, 20 (11): 1151-1154. 10.1038/nbt745.View ArticlePubMed
- Kilby JM, Hopkins S, Venetta TM, DiMassimo B, Cloud GA, Lee JY, Alldredge L, Hunter E, Lambert D, Bolognesi D, Matthews T, Johnson MR, Nowak MA, Shaw GM, Saag MS: Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med. 1998, 4 (11): 1302-1307. 10.1038/3293.View ArticlePubMed
- Heil ML, Decker JM, Sfakianos JN, Shaw GM, Hunter E, Derdeyn CA: Determinants of human immunodeficiency virus type 1 baseline susceptibility to the fusion inhibitors enfuvirtide and T-649 reside outside the peptide interaction site. J Virol. 2004, 78 (14): 7582-7589. 10.1128/JVI.78.14.7582-7589.2004.PubMed CentralView ArticlePubMed
- Neumann T, Hagmann I, Lohrengel S, Heil ML, Derdeyn CA, Krausslich HG, Dittmar MT: T20-insensitive HIV-1 from naive patients exhibits high viral fitness in a novel dual-color competition assay on primary cells. Virology. 2005, 333 (2): 251-262. 10.1016/j.virol.2004.12.035.View ArticlePubMed
- Michel N, Allespach I, Venzke S, Fackler OT, Keppler OT: The Nef protein of human immunodeficiency virus establishes superinfection immunity by a dual strategy to downregulate cell-surface CCR5 and CD4. Curr Biol. 2005, 15 (8): 714-723. 10.1016/j.cub.2005.02.058.View ArticlePubMed
- Venzke S, Michel N, Allespach I, Fackler OT, Keppler OT: Expression of Nef downregulates CXCR4, the major coreceptor of human immunodeficiency virus, from the surfaces of target cells and thereby enhances resistance to superinfection. J Virol. 2006, 80 (22): 11141-11152. 10.1128/JVI.01556-06.PubMed CentralView ArticlePubMed
- Goffinet C, Michel N, Allespach I, Tervo HM, Hermann V, Krausslich HG, Greene WC, Keppler OT: Primary T-cells from human CD4/CCR5-transgenic rats support all early steps of HIV-1 replication including integration, but display impaired viral gene expression. Retrovirology. 2007, 4: 53-10.1186/1742-4690-4-53.PubMed CentralView ArticlePubMed
- Goncalves J, Korin Y, Zack J, Gabuzda D: Role of Vif in human immunodeficiency virus type 1 reverse transcription. J Virol. 1996, 70 (12): 8701-8709.PubMed CentralPubMed
- Ottmann M, Gabus C, Darlix JL: The central globular domain of the nucleocapsid protein of human immunodeficiency virus type 1 is critical for virion structure and infectivity. J Virol. 1995, 69 (3): 1778-1784.PubMed CentralPubMed
- Balzarini J: Targeting the glycans of glycoproteins: a novel paradigm for antiviral therapy. Nat Rev Microbiol. 2007, 5 (8): 583-597. 10.1038/nrmicro1707.View ArticlePubMed
- Campbell S, Gaus K, Bittman R, Jessup W, Crowe S, Mak J: The raft-promoting property of virion-associated cholesterol, but not the presence of virion-associated Brij 98 rafts, is a determinant of human immunodeficiency virus type 1 infectivity. J Virol. 2004, 78 (19): 10556-10565. 10.1128/JVI.78.19.10556-10565.2004.PubMed CentralView ArticlePubMed
- Campbell SM, Crowe SM, Mak J: Virion-associated cholesterol is critical for the maintenance of HIV-1 structure and infectivity. Aids. 2002, 16 (17): 2253-2261. 10.1097/00002030-200211220-00004.View ArticlePubMed
- Jiang S, Lin K, Strick N, Neurath AR: HIV-1 inhibition by a peptide. Nature. 1993, 365 (6442): 113-10.1038/365113a0.View ArticlePubMed
- Wild CT, Shugars DC, Greenwell TK, McDanal CB, Matthews TJ: Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci USA. 1994, 91 (21): 9770-9774. 10.1073/pnas.91.21.9770.PubMed CentralView ArticlePubMed
- Münch J, Standker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pohlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F: Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. Cell. 2007, 129 (2): 263-275. 10.1016/j.cell.2007.02.042.View ArticlePubMed
- Madan RP, Mesquita PM, Cheshenko N, Jing B, Shende V, Guzman E, Heald T, Keller MJ, Regen SL, Shattock RJ, Herold BC: Molecular umbrellas: a novel class of candidate topical microbicides to prevent human immunodeficiency virus and herpes simplex virus infections. J Virol. 2007, 81 (14): 7636-7646. 10.1128/JVI.02851-06.PubMed CentralView ArticlePubMed
- Keppler OT, Yonemoto W, Welte FJ, Patton KS, Iacovides D, Atchison RE, Ngo T, Hirschberg DL, Speck RF, Goldsmith MA: Susceptibility of rat-derived cells to replication by human immunodeficiency virus type 1. J Virol. 2001, 75 (17): 8063-8073. 10.1128/JVI.75.17.8063-8073.2001.PubMed CentralView ArticlePubMed
- Goffinet C, Allespach I, Keppler OT: HIV-susceptible transgenic rats allow rapid preclinical testing of antiviral compounds targeting virus entry or reverse transcription. Proc Natl Acad Sci USA. 2007, 104 (3): 1015-1020. 10.1073/pnas.0607414104.PubMed CentralView ArticlePubMed
- Keppler OT, Allespach I, Schuller L, Fenard D, Greene WC, Fackler OT: Rodent cells support key functions of the human immunodeficiency virus type 1 pathogenicity factor Nef. J Virol. 2005, 79 (3): 1655-1665. 10.1128/JVI.79.3.1655-1665.2005.PubMed CentralView ArticlePubMed
- Keppler OT, Welte FJ, Ngo TA, Chin PS, Patton KS, Tsou CL, Abbey NW, Sharkey ME, Grant RM, You Y, Scarborough JD, Ellmeier W, Littman DR, Stevenson M, Charo IF, Herndier BG, Speck RF, Goldsmith MA: Progress toward a human CD4/CCR5 transgenic rat model for de novo infection by human immunodeficiency virus type 1. J Exp Med. 2002, 195 (6): 719-736. 10.1084/jem.20011549.PubMed CentralView ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.